just have a look at the clinical data for both:
From the BCAL website:
"BCAL approach separates control from IDC Stage 1 and Stage 2 using 12 candidate markers and 2 clinical variables with 85% accuracy and 91% sensitivity (Table) and impressive AUC." (area under the curve I think.) BCAL is developing this for breast cancers only at the moment.
BD1 is below:
from bd1 "The study showed that SubB2M can be used to detect all stages of breast cancer from blood samples with 100% specificity and over 95% sensitivity over healthy controls"
I think that BD1 has a justifiably higher market cap because of the multitude of cancers their diagnostics solutions can identify and the best in class sensitivity/ specificity results.
just have a look at the clinical data for both:From the BCAL...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.005(4.55%) |
Mkt cap ! $41.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.5¢ | $20.99K | 182.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7391 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 225000 | 3 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| BDX (ASX) Chart |